Cargando…
Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers
Immuno-chemotherapy elicit high response rates in B-cell non-Hodgkin lymphoma but heterogeneity in response duration is observed, with some patients achieving cure and others showing refractory disease or relapse. Using a transcriptome-powered targeted proteomics screen, we discovered a gene regulat...
Autores principales: | Emadali, Anouk, Rousseaux, Sophie, Bruder-Costa, Juliana, Rome, Claire, Duley, Samuel, Hamaidia, Sieme, Betton, Patricia, Debernardi, Alexandra, Leroux, Dominique, Bernay, Benoit, Kieffer-Jaquinod, Sylvie, Combes, Florence, Ferri, Elena, McKenna, Charles E, Petosa, Carlo, Bruley, Christophe, Garin, Jérôme, Ferro, Myriam, Gressin, Rémy, Callanan, Mary B, Khochbin, Saadi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Science Inc
2013
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944460/ https://www.ncbi.nlm.nih.gov/pubmed/23828858 http://dx.doi.org/10.1002/emmm.201202034 |
Ejemplares similares
-
BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer
por: Hajmirza, Azadeh, et al.
Publicado: (2018) -
When are the BET factors the most sensitive to bromodomain inhibitors?
por: Khochbin, Saadi
Publicado: (2013) -
A six gene expression signature defines aggressive subtypes and predicts outcome in childhood and adult acute lymphoblastic leukemia
por: Wang, Jin, et al.
Publicado: (2015) -
1q12 chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma
por: Fournier, Alexandra, et al.
Publicado: (2010) -
Selective BET bromodomain inhibition as an antifungal therapeutic strategy
por: Mietton, Flore, et al.
Publicado: (2017)